European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of dementia

Descripción del proyecto

Parámetros retinales como biomarcadores de la disfunción cognitiva en la diabetes de tipo 2

Estudios recientes indican que la diabetes de tipo 2 está asociada con la demencia y la discapacidad cognitiva. En la actualidad no existen biomarcadores fenotípicos para identificar a las personas diabéticas que corren riesgo de desarrollar demencia. El proyecto financiado con fondos europeos RECOGNISED propone la evaluación de la retina como un tejido ontogénicamente derivado del cerebro y, como tal, un posible biomarcador para identificar a pacientes que corren un mayor riesgo de sufrir demencia o discapacidad cognitiva. El consorcio multidisciplinar de quince instituciones europeas investigará los mecanismos comunes implicados en la patogenia retinal y la discapacidad cognitiva en casos de diabetes de tipo 2, y utilizará la retina como una herramienta para identificar a pacientes con mayor riesgo de demencia o deterioro cognitivo. El objetivo último del proyecto es reducir la carga social y económica de la discapacidad cognitiva asociada con la diabetes.

Objetivo

In recent years there is mounting evidence that type 2 diabetes (T2D) is associated with cognitive impairment and dementia, which can be considered as a “new” long-term diabetic co-morbid complication with dramatic consequences for patients and their families and a significant impact for healthcare systems. At present there are no reported phenotypic indicators or reliable tests to identify T2D patients at risk of developing dementia. Since the retina is ontogenically a brain-derived tissue, we propose that the evaluation of retinal parameters related to either neurodegeneration or microvascular disease will be robust and valuable biomarkers to identify those T2D patients at higher risk of developing cognitive impairment and dementia. On this basis the overarching aims of the project are: 1) To investigate the common mechanisms involved in the pathogenesis of DR and cognitive impairment in the T2D. 2) To use the retina as a tool to identifying individuals with T2D at a higher risk of developing cognitive decline or dementia. Our multidisciplinary consortium (RECOGNISED) consist of top research leaders in the field belonging to 15 prestigious institutions as well as EATRIS, IDF-Europe and Alzheimer Europe and 3 SMEs. RECOGNISED will apply innovative approaches to identify the molecular mechanisms involved in the high prevalence of cognitive impairment and dementia in T2D population and will use this knowledge to characterize clinical phenotypes (personalized medicine) based on retinal functional and structural characteristics and serum biomarkers in order to stratify the risk and severity of cognitive decline. Previously collected data from registries, cohorts and biobanks will be appropriately exploited and robust new data will be generated that will guide clinical recommendations and open up new therapeutic strategies. Ultimately, RECOGNISED project will help to reduce the huge societal and economic burden associated with diabetes-related cognitive impairment.

Convocatoria de propuestas

H2020-SC1-BHC-2018-2020

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-SC1-2019-Two-Stage-RTD

Régimen de financiación

RIA - Research and Innovation action

Coordinador

FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA
Aportación neta de la UEn
€ 950 410,00
Dirección
PASSEIG VALL D HEBRON 119-129 EDIFICIO DE RECERCA
08035 Barcelona
España

Ver en el mapa

Región
Este Cataluña Barcelona
Tipo de actividad
Research Organisations
Enlaces
Coste total
€ 950 410,00

Participantes (24)